Paper21396094
Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1.
Hutcheson IR and 7 others. Breast Cancer Res, 2011. Cited by 46 papers, by iCite.
Cite this record
ConductScience Library. Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1. Papers, record 21396094. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/21396094
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Fulvestrant-induced expression of ErbB3 and ErbB4 receptors sensitizes oestrogen receptor-positive breast cancer cells to heregulin β1.
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| ErbB Receptors | Major topic |
| Estradiol | Major topic |
| Neuregulin-1 | Major topic |
| Receptor, ErbB-3 | Major topic |
| Breast Neoplasms | |
| Cell Line, Tumor | |
| Cell Proliferation | |
| Cyclin D1 | |
| Drug Resistance, Neoplasm | |
| Estrogen Receptor Modulators | |
| Female | |
| Fulvestrant | |
| Humans | |
| Intracellular Signaling Peptides and Proteins | |
| Receptor, ErbB-4 | |
| Receptors, Estrogen | |
| Signal Transduction |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Comment in | 21639949 | Endocrine resistance in breast cancer: new roles for ErbB3 and ErbB4. | https://conductscience.org/library/papers/21639949 |
Source PubMed
References57
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 19609946 | Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways. | Int J Cancer | 2010 | https://conductscience.org/library/papers/19609946 | PubMed |
| 2 | 17947476 | Wwox and Ap2gamma expression levels predict tamoxifen response. | Clin Cancer Res | 2007 | https://conductscience.org/library/papers/17947476 | PubMed |
| 3 | 18270579 | Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomas. | PLoS One | 2008 | https://conductscience.org/library/papers/18270579 | PubMed |
| 4 | 19525314 | Target-based therapies in breast cancer: current status and future perspectives. | Endocr Relat Cancer | 2009 | https://conductscience.org/library/papers/19525314 | PubMed |
| 5 | 10698518 | Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancer. | Oncogene | 2000 | https://conductscience.org/library/papers/10698518 | PubMed |
| 6 | 18409071 | Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. | Breast Cancer Res Treat | 2009 | https://conductscience.org/library/papers/18409071 | PubMed |
| 7 | 10537315 | Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo. | Cancer Res | 1999 | https://conductscience.org/library/papers/10537315 | PubMed |
| 8 | 14535532 | The biology of antihormone failure in breast cancer. | Breast Cancer Res Treat | 2003 | https://conductscience.org/library/papers/14535532 | PubMed |
| 9 | 15753463 | Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase. | J Clin Oncol | 2005 | https://conductscience.org/library/papers/15753463 | PubMed |
| 10 | 11390655 | Her4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. | Mol Cell Biol | 2001 | https://conductscience.org/library/papers/11390655 | PubMed |
| 11 | 15084248 | Outcome and human epidermal growth factor receptor (HER) 1-4 status in invasive breast carcinomas with proliferation indices evaluated by bromodeoxyuridine labelling. | Breast Cancer Res | 2004 | https://conductscience.org/library/papers/15084248 | PubMed |
| 12 | 11679632 | gamma -Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase. | Science | 2001 | https://conductscience.org/library/papers/11679632 | PubMed |
| 13 | 12820409 | mRNA expression of the type I growth factor receptors in the human breast cancer cells MCF-7: regulation by estradiol and tamoxifen. | Anticancer Res | 2003 | https://conductscience.org/library/papers/12820409 | PubMed |
| 14 | 8617750 | HER4-mediated biological and biochemical properties in NIH 3T3 cells. Evidence for HER1-HER4 heterodimers. | J Biol Chem | 1996 | https://conductscience.org/library/papers/8617750 | PubMed |
| 15 | 1333787 | Expression of the ERBB3 gene product in breast cancer. | Br J Cancer | 1992 | https://conductscience.org/library/papers/1333787 | PubMed |
| 16 | 11522647 | Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. | Cancer Res | 2001 | https://conductscience.org/library/papers/11522647 | PubMed |
| 17 | 7912565 | Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy. | Breast Cancer Res Treat | 1994 | https://conductscience.org/library/papers/7912565 | PubMed |
| 18 | 19481955 | The upgraded role of HER3 and HER4 receptors in breast cancer. | Crit Rev Oncol Hematol | 2010 | https://conductscience.org/library/papers/19481955 | PubMed |
| 19 | 9788438 | c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer. | Oncogene | 1998 | https://conductscience.org/library/papers/9788438 | PubMed |
| 20 | 8932874 | Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes. | Breast Cancer Res Treat | 1996 | https://conductscience.org/library/papers/8932874 | PubMed |
Cited by34
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 46 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42353156 | Molecular Mechanisms Underlying Recurrence in Triple-Positive Breast Cancer (ER+/PR+/HER2+) and Potential Repurposing of Multi-Target Inhibitors. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42353156 | PubMed |
| 41392922 | Patritumab deruxtecan in breast cancer treatment: a drug evaluation. | Future Oncol | 2025 | https://conductscience.org/library/papers/41392922 | PubMed |
| 40908353 | Patritumab deruxtecan in HR+HER2- advanced breast cancer: a phase 2 trial. | Nat Med | 2025 | https://conductscience.org/library/papers/40908353 | PubMed |
| 39995133 | HER3-targeting Antibody-drug Conjugates Therapy for Solid Tumors: Recent Advances and Future Potentials. | Curr Med Chem | 2026 | https://conductscience.org/library/papers/39995133 | PubMed |
| 39020378 | HER3 receptor and its role in the therapeutic management of metastatic breast cancer. | J Transl Med | 2024 | https://conductscience.org/library/papers/39020378 | PubMed |
| 38542136 | EB1089 Increases the Antiproliferative Response of Lapatinib in Combination with Antiestrogens in HER2-Positive Breast Cancer Cells. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38542136 | PubMed |
| 38394152 | Boolean modeling of breast cancer signaling pathways uncovers mechanisms of drug synergy. | PLoS One | 2024 | https://conductscience.org/library/papers/38394152 | PubMed |
| 38339304 | Molecular Atlas of HER2+ Breast Cancer Cells Treated with Endogenous Ligands: Temporal Insights into Mechanisms of Trastuzumab Resistance. | Cancers (Basel) | 2024 | https://conductscience.org/library/papers/38339304 | PubMed |
| 37947595 | HER3: Toward the Prognostic Significance, Therapeutic Potential, Current Challenges, and Future Therapeutics in Different Types of Cancer. | Cells | 2023 | https://conductscience.org/library/papers/37947595 | PubMed |
| 36764093 | Targeting HER3 for cancer treatment: a new horizon for an old target. | ESMO Open | 2023 | https://conductscience.org/library/papers/36764093 | PubMed |
| 36551663 | HER3 Alterations in Cancer and Potential Clinical Implications. | Cancers (Basel) | 2022 | https://conductscience.org/library/papers/36551663 | PubMed |
| 36142451 | Comprehensive Transcriptomic and Proteomic Analyses Identify a Candidate Gene Set in Cross-Resistance for Endocrine Therapy in Breast Cancer. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36142451 | PubMed |
| 35254385 | Modulation of the Estrogen/erbB2 Receptors Cross-talk by CDK4/6 Inhibition Triggers Sustained Senescence in Estrogen Receptor- and ErbB2-positive Breast Cancer. | Clin Cancer Res | 2022 | https://conductscience.org/library/papers/35254385 | PubMed |
| 33608318 | Thirty Years of HER3: From Basic Biology to Therapeutic Interventions. | Clin Cancer Res | 2021 | https://conductscience.org/library/papers/33608318 | PubMed |
| 33500629 | Gastric Cancer Harboring an ERBB3 Mutation Treated with a Pyrotinib-Irinotecan Combo: A Case Study. | Onco Targets Ther | 2021 | https://conductscience.org/library/papers/33500629 | PubMed |
| 33420373 | A feed-forward loop between SorLA and HER3 determines heregulin response and neratinib resistance. | Oncogene | 2021 | https://conductscience.org/library/papers/33420373 | PubMed |
| 33176725 | Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany. | BMC Cancer | 2020 | https://conductscience.org/library/papers/33176725 | PubMed |
| 31756933 | Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials. | Cancers (Basel) | 2019 | https://conductscience.org/library/papers/31756933 | PubMed |
| 31519989 | ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics. | Oncogene | 2020 | https://conductscience.org/library/papers/31519989 | PubMed |
| 30314968 | Combined Blockade of Activating ERBB2 Mutations and ER Results in Synthetic Lethality of ER+/HER2 Mutant Breast Cancer. | Clin Cancer Res | 2019 | https://conductscience.org/library/papers/30314968 | PubMed |
Genes16
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/21396094
GET https://conductscience.org/api/papers/v1/21396094/references?page=2